阿达木单抗联合塞来昔布治疗强直性脊柱炎效果观察

Efficacy of Adalimumab Combined with Celecoxib in the Treatment of Ankylosing Spondylitis

目的本研究将阿达木单抗塞来昔布联合应用于AS的治疗中,并对该治疗方式的应用效果进行分析。方法选取2021年1月—2022年10月本院肾病风湿科收治的60例强直性脊柱炎为研究对象,依照治疗方式的不同将患者分为研究组(n=30)和参比组(n=30)。对参比组采取常规治疗法,研究组在参照组的基础上采用阿达木单抗联合塞来昔布的治疗,治疗后对比两组患者的临床症状恢复情况、炎症因子水平、生活质量以及临床疗效。结果治疗后,研究组BASDAI指数、BASFI指数低于参比组(P<0.05);而质量综合评估问卷(GQOL-74)中的社会功能、物质生活、心理功能以及躯体功能评分高于参比组(P<0.05);同时研究组的临床有效率高于参比组的临床有效率(P<0.05)。结论在对AS患者进行治疗时采取阿达木单抗与塞来昔布的联合治疗能够有效降低患者机体的炎症因子水平,促进疾病的恢复,达到提高临床疗效以及患者生活质量水平的目的。

Objective In this study,adalimumab combined with celecoxib was used in the treatment of AS,and the application effect of the treatment was analyzed.Methods 60 cases of ankylosing spondylitis admitted to the Department of Nephrology and Rheumatology of our hospital from January 2021 to October 2022 were included.According to different treatment methods,the subjects were divided into study group(n=30)and reference group(n=30).The reference group was treated with conventional therapy,on the basis of which adalimumab combined with celecoxib was given to the study group.After treatment,the recovery of clinical symptoms,levels of inflammatory factors,quality of life and clinical efficacy of the two groups were compared.Results After treatment,the BASDAI index and BASFI index of the study group were lower than those of the reference group(P<0.05);The scores of social function,material life,psychological function and physical function in GQOL-74 were higher than those in the reference group(P<0.05).At the same time,the clinical effective rate of the study group(93.33%)was higher than that of the reference group(73.33%)(P<0.05).Conclusion In the treatment of AS patients,adalimumab combined with celecoxib can effectively reduce the level of inflammatory factors in the body,promote the recovery of the disease,and achieve the purpose of improving the clinical efficacy and the quality of life of patients.